Skip to main content
Equibles
MNPR logo

MNPR · Monopar Therapeutics

Track MNPR — free

Use MNPR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MNPR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$78.96 -5.02 (-5.98%) At close · Oct 9
Russell 2000 member Rebalance outlook locked
Market Cap
$529.99M
Shares
6.71M
Volume · Oct 9 135.85K Avg daily vol (3M) 212.17K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$78.96 Open$83.47 Day$78.80–84.04 52W close$50.12–123.84 Avg vol 30d155K Short int1.1M · 16.2% float · 6.0d Short vol52% DataJan 2020–Oct 2026 Filing10-Q · Aug 12

Up next

Latest filing: 10-Q
filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-21.8%
Trailing year
Short interest
16.2%
Latest settlement · 6.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 14.8 · calm Equity put/call 0.56
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +3%
above
Price vs 50-day avg −24%
below
RSI (14) 29
oversold
MACD trend Positive
52-week position 39%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −28%
trailing
6-month return +44%
trailing
YTD return +21%
this year
Relative strength +34%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $104 › 200d $77 — 50d above 200d
Institutional flow Accumulating
3 of 95 funds reported for Sep 30 · net +17 sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.18% of float · ▲ +28.7% MoM · 6.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
95 holders — near 3-yr high, broad support
Squeeze score 62
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 67%
annualized · 1-yr
Max drawdown −51%
past year
ATR 6.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+3% Bullish
Price vs 50-day avg
−24% Bearish
RSI (14)
29 Neutral
MACD trend
Positive Bullish
52-week position
39% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $104 › 200d $77 — 50d above 200d
Institutional flow Accumulating
3 of 95 funds reported for Sep 30 · net +17 sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.18% of float · ▲ +28.7% MoM · 6.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
95 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $50 Now $79 · 39% Range high $124
vs 200-day avg +3% vs 50-day avg -24%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MNPR
Monopar Therapeutics
this stock
$529.99M +20.9% — — 16.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $129.29B +12.5% +46.2% 29.7 1.8%
MRNA
Moderna, Inc.
 $89.83B +663.0% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $76.86B -3.3% +20.8% 18.5 2.1%
CSLLY
Csl Ltd
 $61.83B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
96
% held
92.7%
Reported
3 of 95
Top holder
Jupiter Topco LLC
Held Float
View
Held by Funds
Fund positions
100
View
Short & Settlement
Short Interest Rising
Shares short
1.1M
Days to cover
6.0d
Change
+242.1K sh
View
Short Volume
Short vol %
52%
As of
Oct 9, 2026
Short Total
View
Fails to Deliver
FTD shares
1.5K
Value
$175.2K
As of
Sep 3, 2026
View
Off-Exchange
Off-exchange %
36.3%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-13.7M
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 12, 2026
This year
16
View
Proposed Sales
Value
$1.3M
Shares
16.8K
Filed
Oct 1, 2026
View
Earnings & Events
Investor Relations
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
MNPR +1.3% -28.4% +44.4% -0.9% +20.9%
SPY +1.2% +1.9% +9.9% +2.1% +14.2%
vs SPY +0.1% -30.3% +34.5% -3.0% +6.8%
Key facts CIK 1645469 CUSIP 61023L207 13F (30d) 4 filings 4 filers Visit website Investor relations